Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.92 |
| ▸ | ITGA5 | P08648 | 8/20 | 0.92 |
| ▸ | ITGAV | P06756 | 14/20 | 0.68 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.60 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.48 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18339179 | 1.00 | ITGB1 (0.92) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL18349161 | 1.00 | ITGB1 (0.92) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL16598433 | 0.97 | ITGB1 (0.90) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL18349180 | 0.97 | ITGB1 (0.90) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL18339180 | 0.97 | ITGB1 (0.90) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL18349179 | 0.97 | ITGB1 (0.89) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL16598267 | 0.97 | ITGB1 (0.89) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL16598271 | 0.97 | ITGB1 (0.89) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL20558468 | 0.96 | ITGB1 (1.00) | ITGB1ITGA5ITGAVITGA4ITGB3 | |
| SCHEMBL18348968 | 0.96 | ITGB1 (1.00) | ITGB1ITGA5ITGAVITGA4ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-11-01 | — | — | US | disclosed |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | UNIV CALIFORNIA (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | UNIV CALIFORNIA (US) | 2016-12-29 | — | — | US | disclosed |
| EP-3052515-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | The Regents of the University of California (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015048819-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | ITGB1 1/4885ITGA5 15/4885ITGAV 2/4885 |
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | ITGB1, ITGAV, ITGA1 | ITGB1 1/4885ITGA5 15/4885ITGAV 2/4885 |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | ITGB1 1/4885ITGA5 15/4885ITGAV 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.